This builds upon its initial approval in May 2024 for adults aged 60 years and older, which makes mRESVIA the second approved ...

The U.S. Food and Drug Administration on Thursday expanded the use of Moderna's respiratory syncytial virus vaccine to a ...

The FDA expanded its approval of Moderna's RSV vaccine on Thursday to include adults under age 60 at increased risk of the ...

The FDA expanded the approval of Moderna’s RSV vaccine, extending the license to include more adults and giving the company a ...

For the 2025-2026 respiratory viral season, Moderna intends to have mResvia available for both FDA-approved patient populations.

The FDA approved mResvia for the prevention of RSV in people ages 18 to 59 years who are at increased risk for severe disease ...

Technological advances in the design and delivery of mRNA have catalysed the rapid development of mRNA COVID-19 vaccines by ...

RESVIA is now authorized for use in adults aged 18–59 years with an increased risk of respiratory syncytial virus-related ...

The U.S. Food and Drug Administration expanded approval of Moderna Inc.'s (NASDAQ: MRNA) respiratory syncytial virus vaccine.

First, let's back up a bit and take a look at the Moderna story, from the glory days of a few years ago to its troubles today ...

The Food and Drug Administration expanded the approval of Moderna’s RSV vaccine on Thursday, extending the license to include ...